Trial Profile
Conversion From Fast Acting Oral Opioids to Abstral (SL Fentanyl) in Opioid Tolerant Cancer Patients With Breakthrough Pain
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Orexo
- 11 Aug 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2010-020239-38).
- 19 Jun 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 19 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.